| 注册
首页|期刊导航|南方医科大学学报|DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌

DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌

郭伟伟 刘莉 吴德华

南方医科大学学报Issue(5):674-678,5.
南方医科大学学报Issue(5):674-678,5.DOI:10.3969/j.issn.1673-4254.2014.05.16

DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌

Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arte-rial chemoembolization for hepatocellular carcinoma:safety and efficacy

郭伟伟 1刘莉 2吴德华1

作者信息

  • 1. 南方医科大学南方医院放疗科,广东 广州 510515
  • 2. 南方医科大学南方医院肝脏肿瘤中心,广东 广州 510515
  • 折叠

摘要

Abstract

Objective To explore the clinical efficacy of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy combined with transcatheter arterial chemoembolization (TACE) for treatment of hepatocellular carcinoma. Methods Thirty patients with hepatocellular carcinoma treated with TACE combined with DC-CIK cell therapy and 38 patients treated with TACE alone (control group) were compared for progression-free survival time, overall survival time, quality of life, and treatment-related adverse events. Results The median progression-free survival was 16 months in the combined treatment group as compared with 7 months in the control group (P=0.033). The median overall survival time was 24 months in the combined treatment group and 13 months in the control group, with 1-year overall survival rates of 80% and 75.2%, respectively, showing no significant differences between the two groups (P=0.089). Multivariate analysis indicated that Barcelona-Clinic-Liver-Cancer (BCLC) staging and AFP level before treatment were two independent risk factors of progression-free survival time, and BCLC stage served also as an independent risk factor of the overall survival time. Ten patients in the combined treatment group (33.3%) showed improved quality of life, as compared with 4 patients (10.5%) in the control group (P=0.034). Three patients receiving DC-CIK treatment experienced fever and 1 had allergic reaction, and the symptoms remitted after expectant treatment. Conclusion Compared with TACE alone, DC-CIK immunotherapy combined with TACE can improve the patients' progression-free survival time but not the overall survival time. The combined therapy also improves the quality of life of the patients with advanced hepatocellular carcinoma and shows good treatment safety.

关键词

原发性肝癌/肝动脉化疗栓塞/细胞免疫治疗/树突状细胞-细胞因子诱导的杀伤细胞

Key words

hepatocellular carcinoma/transcatheter arterial chemoembolization/immunotherapy/dendritic cells-cytokine induced killer cells

引用本文复制引用

郭伟伟,刘莉,吴德华..DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌[J].南方医科大学学报,2014,(5):674-678,5.

基金项目

国家自然科学基金(81172856)@@@@Supported by National Natural Science Foundation of China (81172856) (81172856)

南方医科大学学报

OA北大核心CSCDCSTPCDMEDLINE

1673-4254

访问量0
|
下载量0
段落导航相关论文